Based on observed high levels of TGF-β1 in healthy aging individuals and reduced TGFβR2 levels in AD patients, a hypothesis has been proposed that suggests using the first to address the latter, thereby preventing the progression of AD [286]. The gene discussed is TGFB1; the disease is Alzheimer disease.